Marker Therapeutics
MRKR
63 hedge funds and large institutions have $44.7M invested in Marker Therapeutics in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 25 reducing their positions, and 15 closing their positions.
203% more call options, than puts
Call options by funds: $749K | Put options by funds: $247K
0.91% less ownership
Funds ownership: 32.74% → 31.83% (-0.91%)
15% less funds holding
Funds holding: 74 → 63 (-11)
41% less capital invested
Capital invested by funds: $75.8M → $44.7M (-$31.1M)
52% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 25
67% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.2M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$1.19M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$372K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$260K |
| 5 |
MLIC
Mandatum Life Insurance Company
Helsinki,
Finland
|
+$203K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.32M |
| 2 |
Two Sigma Advisers
New York
|
-$976K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$554K |
| 4 |
E
Ergoteles
New York
|
-$383K |
| 5 |
D.E. Shaw & Co
New York
|
-$359K |
MRKR Hedge Fund Activity: Q3 2021 in Review
63 of the 5,729 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q3 2021, worth a combined $44.7M — down 41% from $75.8M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of MRKR and 5 opened new positions — a net loss of 10 holders — while 25 trimmed existing stakes and 12 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.2M. The largest seller was Millennium Management, cutting an estimated $1.32M.
- 63 institutional investors held Marker Therapeutics (MRKR) as of Q3 2021, down from 74 in Q2 2021.
- Funds reported $44.7M of Marker Therapeutics stock for Q3 2021, down 41% quarter-over-quarter.
- 5 funds opened new Marker Therapeutics positions in Q3 2021 and 15 closed out, a net change of -10 holders.
- The largest Marker Therapeutics buyer in Q3 2021 was Renaissance Technologies, an estimated $1.2M added.
- The largest Marker Therapeutics seller in Q3 2021 was Millennium Management, an estimated $1.32M sold.
Based on aggregated 13F filings for Q3 2021.